$77.61
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
ANI Pharmaceuticals Plans to Appeal Trial Court Rulings in CG Oncology Case
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
ANIP: Lowering target price to $77.00
Overview
52-week range
$60
$100
45% of range
Avg surprise (last 3)
+45.3%
Avg reaction (last 2)
-4.9%
0% positive
Latest IV / EM
53%
EM ±12.2% · $80 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 8, 2026 | Mar/2026 | $1.68 | $0.96 | +75.0% | +22.6% | -2.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.13 | — | — | — | — | financials |
| Fri Aug 8, 2025 | Jun/2025 | $1.38 | $1.02 | +35.3% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $1.37 | $1.09 | +25.7% | — | -7.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.27 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.14 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.82 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.45 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.29 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Aug 14, 2026 | Jun/2026 | OTHER | $1.67 | $1.38 | +21.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $39M | — | $36M | $14M | $26M | — | $-21M | $5M |
| Net income | $29M | — | $27M | $9M | $16M | — | $-24M | $-2M |
| EPS (diluted) | $1.28 | — | $1.13 | $0.36 | $0.69 | — | $-1.27 | $-0.14 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $311M | $286M | $263M | $218M | $150M | $145M | $145M | $240M |
| Inventory | $143M | $143M | $146M | $138M | $137M | $137M | $148M | $125M |
| Total current assets | $747M | $753M | $698M | $603M | $536M | $528M | $521M | $555M |
| Total assets | $1.42B | $1.44B | $1.41B | $1.34B | $1.29B | $1.28B | $1.29B | $921M |
| Long-term debt | $286M | $292M | $298M | $301M | $305M | $309M | $313M | $284M |
| Total liabilities | $860M | $900M | $902M | $881M | $849M | $855M | $857M | $440M |
| Total equity | $562M | $541M | $506M | $437M | $419M | $404M | $406M | $456M |